Could a cholesterol drug prevent first heart attacks in High-Risk patients?
NCT ID NCT07615179
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study observed over 4,500 adults with atherosclerotic cardiovascular disease who had never had a heart attack or stroke. Researchers compared those taking alirocumab (a cholesterol-lowering drug) to those not on similar therapy, using real-world data to see if the drug reduced the risk of heart attack, stroke, or death. Because it's observational, it can suggest but not prove whether alirocumab helps prevent these first-time events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alirocumab
What this could lead to
If this study shows alirocumab reduces heart attacks and strokes, it could support using this drug more broadly in people with artery disease who haven't yet had a major event.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It cannot prove cause and effect, and findings may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanofi
Bridgewater, New Jersey, 08807, United States